Dehydromonocrotaline

Overview

Dehydromonocrotaline is a mitochondrial respiratory chain complex I NADH oxidase inhibitor, with a IC 50 of 62.06 μM and a K i of 8.1 μM in rats. Dehydromonocrotaline exerts non-competitive inhibitory effects by modifying cysteine thiol groups on complex I , and does not bind to the NADH-binding site. Dehydromonocrotaline dissipates mitochondrial membrane potential and reduces ATP levels. Dehydromonocrotaline can be used in studies related to hepatotoxicity, pulmonary hypertension and liver tumors.

Application

Products | Products > Disease Areas > Pulmonary Hypertension | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Endogenous Metabolite

Product Information

• Catalog No.: HY-N9279
• CAS No.: 23291-96-5
• Molecular Formula: C16H21NO6
• Molecular Weight: 323.34
• Purity: 99.98%
• Storage: -80°C, protect from light, stored under nitrogen
• Solubility: ≥ 2.5 mg/mL (7.73 mM); Clear solution
• Availability: In-stock

Source

Original product source